Prognostic value of serum phosphoglycerate dehydrogenase and glycine levels in breast cancer
View abstract on PubMed
Summary
This summary is machine-generated.This study found lower Phosphoglycerate dehydrogenase (PHGDH) levels and higher glycine concentrations in breast cancer patients. These findings suggest PHGDH and glycine may serve as prognostic factors for breast cancer development.
Area Of Science
- Biochemistry
- Oncology
- Metabolic pathways
Background
- Breast cancer (BC) is a leading global health concern, particularly among women.
- Phosphoglycerate dehydrogenase (PHGDH) is a key enzyme in serine biosynthesis, linked to glycolysis.
- Altered serine metabolism is increasingly recognized in cancer progression.
Purpose Of The Study
- To investigate the levels of PHGDH and glycine in breast cancer patients.
- To explore the potential of PHGDH and glycine as biomarkers for breast cancer.
Main Methods
- Analysis of 135 blood samples (65 BC patients, 70 controls) from December 2022 to March 2023.
- Measurement of serum PHGDH and glycine using enzyme-linked immunosorbent assay (ELISA).
- Assessment of complete blood count (CBC) parameters, including neutrophil/lymphocyte ratio.
Main Results
- Patients with breast cancer exhibited a significantly increased neutrophil/lymphocyte ratio (p < 0.01).
- A significant decrease in serum PHGDH levels was observed in breast cancer patients compared to controls (p < 0.01).
- Serum glycine levels were significantly elevated in breast cancer patients versus the control group (p < 0.01).
Conclusions
- Reduced PHGDH levels and elevated glycine concentrations are associated with breast cancer.
- These metabolic alterations may function as prognostic indicators in breast cancer development.
- Further research is warranted to validate PHGDH and glycine as reliable biomarkers for BC.

